2025. EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine. 9, 6 (Nov. 2025), s633. DOI:https://doi.org/10.25251/jg65bt44.